Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 283

1.

Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.

Su X, Xu B, Yan B, Qiao X, Wang L.

PLoS One. 2017 Nov 2;12(11):e0187550. doi: 10.1371/journal.pone.0187550. eCollection 2017.

2.

Determination of the optimal target level of proteinuria in the management of patients with glomerular diseases by using different definitions of proteinuria.

Kee YK, Yoon CY, Kim SJ, Moon SJ, Kim CH, Park JT, Lim BJ, Chang TI, Kang EW, Kie JH, Yoo TH, Jeong HJ, Kang SW, Han SH.

Medicine (Baltimore). 2017 Nov;96(44):e8154. doi: 10.1097/MD.0000000000008154.

3.

Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.

Jaurretche S, Antogiovanni N, Perreta F.

Mol Genet Metab Rep. 2017 May 23;12:41-43. doi: 10.1016/j.ymgmr.2017.05.007. eCollection 2017 Sep.

4.

Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe.

Gluba-Brzózka A, Franczyk B, Rysz J.

Nutrients. 2017 Apr 10;9(4). pii: E374. doi: 10.3390/nu9040374. Review.

5.

Impact of acute kidney injury on long-term mortality and progression to chronic kidney disease among critically ill children.

Al-Otaibi NG, Zeinelabdin M, Shalaby MA, Khathlan N, Mashat GD, Zahrani AA, NoorSaeed SM, Shalabi NM, Alhasan KA, Sharief SN, Albanna AS, Kari JA.

Saudi Med J. 2017 Feb;38(2):138-142. doi: 10.15537/smj.2017.2. 16012.

6.

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group.

Diabetes Obes Metab. 2017 Mar;19(3):387-393. doi: 10.1111/dom.12829. Epub 2017 Jan 25.

7.

Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review.

Tsai CW, Lin SY, Kuo CC, Huang CC.

PLoS One. 2017 Jan 20;12(1):e0170393. doi: 10.1371/journal.pone.0170393. eCollection 2017. Review.

8.

Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study.

Shu D, Xu F, Su Z, Zhang J, Chen C, Zhang J, Ding X, Lv Y, Lin H, Huang P.

BMC Nephrol. 2017 Jan 7;18(1):11. doi: 10.1186/s12882-016-0429-x.

9.
10.

Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.

Chen YH, Tarng DC, Chen HS.

PLoS One. 2016 Nov 3;11(11):e0165750. doi: 10.1371/journal.pone.0165750. eCollection 2016.

11.

Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study.

de Boer IH, Gao X, Cleary PA, Bebu I, Lachin JM, Molitch ME, Orchard T, Paterson AD, Perkins BA, Steffes MW, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1969-1977. Epub 2016 Oct 24.

12.

Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.

Tuttle KR, McKinney TD, Davidson JA, Anglin G, Harper KD, Botros FT.

Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.

13.

Prevalence and recognition of chronic kidney disease in Stockholm healthcare.

Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR, Runesson B, Barany P, Ärnlöv J, Jernberg T, Wettermark B, Elinder CG, Carrero JJ.

Nephrol Dial Transplant. 2016 Dec;31(12):2086-2094. Epub 2016 Oct 13.

14.

Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade.

Palevsky PM, Zhang JH, Seliger SL, Emanuele N, Fried LF; VA NEPHRON-D Study.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1944-1953. Epub 2016 Sep 27.

15.

Chronic Kidney Disease in Primary Care: Outcomes after Five Years in a Prospective Cohort Study.

Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.

PLoS Med. 2016 Sep 20;13(9):e1002128. doi: 10.1371/journal.pmed.1002128. eCollection 2016 Sep.

16.

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1989-1998. Epub 2016 Aug 25.

17.

Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014.

Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH.

JAMA. 2016 Aug 9;316(6):602-10. doi: 10.1001/jama.2016.10924.

18.

Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study.

Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1735-1743. doi: 10.2215/CJN.02170216. Epub 2016 Aug 11.

20.

Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.

Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1752-1759. doi: 10.2215/CJN.13091215. Epub 2016 Jul 21.

Supplemental Content

Loading ...
Support Center